<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Botryomycosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Botryomycosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Botryomycosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tahaniyat Lalani, MBBS, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John C Murray, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandra Nelson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Botryomycosis is a chronic suppurative infection characterized by a granulomatous inflammatory response to bacterial pathogens; it may present with cutaneous or, less commonly, visceral involvement [<a href="#rid1">1</a>]. Botryomycosis was first described in a horse in 1870 by a German pathologist. The name "botryomycosis" was coined in 1884, but its bacterial nature was not discovered until 1919 [<a href="#rid2">2</a>]. The term "botryomycosis" is derived from the Greek word "botrys" (meaning "bunch of grapes") and "mycosis" (a misnomer, due to the presumed fungal etiology in early descriptions). Other terms used to describe botryomycosis include bacterial pseudomycosis, staphylococcal actinophytosis, granular bacteriosis, and actinobacillosis.</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Botryomycosis is a relatively uncommon disease, and its description is limited to case reports in children and adults. It occurs more commonly among immunocompromised patients, although infection in immunocompetent patients has also been described [<a href="#rid3">3-5</a>]. The specific role of the host immune response is not fully understood [<a href="#rid6">6-8</a>].</p><p>Risk factors associated with botryomycosis include [<a href="#rid6">6,7,9-13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Alcoholism</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus</p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection</p><p class="bulletIndent1"><span class="glyph">●</span>Cystic fibrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic granulomatous disease</p><p class="bulletIndent1"><span class="glyph">●</span>Trauma</p><p class="bulletIndent1"><span class="glyph">●</span>Surgery</p><p></p><p class="headingAnchor" id="H3"><span class="h1">MICROBIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>The most common organism causing botryomycosis is <em>Staphylococcus aureus</em>. Less common pathogens include gram-negative bacteria (<em>Pseudomonas aeruginosa</em>, <em>Escherichia coli</em>, <em>Serratia</em>, and <em>Proteus</em>), gram-positive cocci (coagulase-negative staphylococci, streptococci, micrococci), and anaerobes (<em>Actinobacillus</em>, <em>Peptostreptococcus</em>, and <em>Cutibacterium</em> [formerly <em>Propionibacterium</em>]<em> acnes</em>) [<a href="#rid3">3,14</a>].</p><p>The pathogenesis of botryomycosis is not fully understood; it is thought to involve a combination of potential factors including an inciting event (such as trauma), the number of organisms inoculated, the virulence of the infecting pathogen, and host susceptibility to infection [<a href="#rid1">1,6,15,16</a>]. Visceral botryomycosis is more likely to occur in patients who are immunosuppressed [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Botryomycosis may present as cutaneous or visceral disease. Cutaneous botryomycosis involves the skin and subcutaneous tissue; visceral botryomycosis involves internal organs such as lungs, liver, or brain.</p><p class="headingAnchor" id="H5"><span class="h2">Cutaneous disease</span><span class="headingEndMark"> — </span>Cutaneous botryomycosis is the most common form of botryomycosis and usually occurs following cutaneous inoculation of bacteria due to trauma, surgery, or the presence of a foreign body [<a href="#rid17">17-19</a>]. Lesions characteristically develop slowly and may evolve and enlarge for several months and, rarely, even years.</p><p>Most patients present with subcutaneous nodules, but others may develop verrucous lesions or nonhealing ulcers associated with draining sinuses or fistulae  (<a class="graphic graphic_picture graphicRef76152" href="/z/d/graphic/76152.html" rel="external">picture 1</a>). Drainage from these lesions is usually purulent and may contain small yellowish "grains" resembling the sulfur granules seen in actinomycosis. (See  <a class="medical medical_review" href="/z/d/html/3411.html" rel="external">"Cervicofacial actinomycosis"</a>.)</p><p>Occasionally, infection may involve contiguous soft tissues such as the subcutaneous tissue, muscles, tendons, and bone. Mucosal involvement of areas such as the tongue and nasal septum, lymph nodes or visceral involvement has also been described [<a href="#rid5">5,20,21</a>]. Disseminated infection can follow cutaneous disease in the setting of severe immunosuppression [<a href="#rid22">22</a>].</p><p>Patients infected with HIV may present with atypical lesions resembling conditions such as prurigo nodularis, lichen simplex chronicus, or sporotrichosis [<a href="#rid7">7,23</a>]. No correlation between CD4 count and susceptibility to botryomycosis has been described. (See  <a class="medical medical_review" href="/z/d/html/3703.html" rel="external">"Fever and rash in patients with HIV"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Visceral disease</span><span class="headingEndMark"> — </span>Visceral botryomycosis occurs most commonly in the lung, although involvement of other organs including liver, spleen, kidney, and brain has also been described [<a href="#rid2">2</a>]. Systemic symptoms such as fever, fatigue, or weight loss may or may not be present.</p><p>Symptoms associated with pulmonary botryomycosis include chronic cough, dyspnea, hemoptysis, and chest wall pain [<a href="#rid14">14,24</a>]. Clinical examination may be normal or demonstrate diminished breath sounds or rhonchi over the consolidated lung. Given the prolonged duration and nature of the symptoms, pulmonary botryomycosis may be mistaken for malignancy [<a href="#rid24">24</a>].</p><p>Botryomycosis involving the liver, spleen, or kidney tends to present with chronic abdominal pain and local tenderness to palpation [<a href="#rid9">9,25</a>]. Ultrasonography or computerized tomography reveals a mass lesion of the abdomen suspicious for an abscess or malignancy.</p><p>Cerebral botryomycosis has been described in association with dental caries or after oral surgery [<a href="#rid25">25-27</a>]. Focal neurological deficits, seizures, or signs of meningitis may occur, and some patients develop a fulminant course [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H7"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Conditions that mimic botryomycosis are summarized below; in general, the diagnoses are distinguished by histopathology and culture.</p><p class="bulletIndent1"><span class="glyph">●</span>Actinomycosis – Both actinomycosis and botryomycosis can present with cutaneous or visceral involvement. Cutaneous disease due to both actinomycosis and botryomycosis can be associated with drainage containing small "grains." (See  <a class="medical medical_review" href="/z/d/html/6992.html" rel="external">"Nonresolving pneumonia", section on 'Nocardia and Actinomyces'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Nocardia</em> – Like botryomycosis, nocardiosis may present with cutaneous or visceral involvement; it is generally observed in immunocompromised patients. (See  <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">"Nocardia infections: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fungal infection – A number of fungal infections present with cutaneous lesions resembling botryomycosis; these include eumycetoma, chromoblastomycosis, and phaeohyphomycosis. (See  <a class="medical medical_review" href="/z/d/html/2439.html" rel="external">"Eumycetoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mycobacterial infection – Cutaneous tuberculosis, tuberculous lymphadenitis, and atypical mycobacterial infection may present with skin lesions and draining sinus tracts resembling botryomycosis. (See  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis"</a> and  <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">"Overview of nontuberculous mycobacterial infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sporotrichosis – Sporotrichosis occurs following cutaneous inoculation and presents with lymphocutaneous spread; in rare cases, pulmonary involvement may be observed. (See  <a class="medical medical_review" href="/z/d/html/2457.html" rel="external">"Clinical features and diagnosis of sporotrichosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous leishmaniasis – Cutaneous leishmaniasis causes a spectrum of cutaneous disease and can resemble botryomycosis. Epidemiologic exposure is an important component of the clinical history. (See  <a class="medical medical_review" href="/z/d/html/5689.html" rel="external">"Cutaneous leishmaniasis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin cancer – Botryomycosis can mimic the appearance of squamous cell carcinoma or the violaceous lesions of Kaposi sarcoma; these are distinguished by histopathology. (See  <a class="medical medical_review" href="/z/d/html/16225.html" rel="external">"Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7729.html" rel="external">"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Laboratory evaluation including biopsy for histopathology and culture are needed to differentiate botryomycosis from other diagnoses listed above [<a href="#rid20">20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of drainage for grains – Pus from draining sinuses should be collected on sterile gauze or aspirated and transferred to a sterile container. Granules should be picked up using a needle or forceps and crushed between two slides. Anecdotal reports associate certain pathogens with a characteristic grain color. <em>S. aureus</em> is classically associated with pale yellow or white granules.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of granules itself does not establish diagnosis of botryomycosis since they can be present in actinomycosis and nocardiosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Botryomycosis may be distinguished from actinomycosis and mycetoma in that botryomycosis granules are of variable size and shape up to 500 microns in diameter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gram staining (using traditional methods or the Brown-Brenn stain) or <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">silver nitrate</a> staining (using the Grocott-Gomori method) of crushed granules or biopsy specimens to identify nonfilamentous bacteria – Rarely, gram-positive cocci ≤1 micron in diameter are present in the exudate surrounding the granule and occur singly, in pairs, or in small clumps. In contrast, actinomycetes are branching filamentous bacteria ≤1 micron in diameter, while fungi causing mycetoma have hyphae that are at least 2 microns wide. These distinctions are important for guiding clinical management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Routine bacterial, fungal, and mycobacterial cultures – Growth of bacterial pathogens would support diagnosis of botryomycosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The histopathologic appearance of botryomycosis is characterized by a central focus of necrosis surrounded by a chronic inflammatory reaction containing histiocytes, epithelioid cells, multinucleated giant cells, and fibrosis [<a href="#rid25">25</a>]. Unlike the sulfur granules seen in actinomycosis (which contain filamentous branching organisms), the granules seen in botryomycosis (Bollinger granules) contain bacteria surrounded by an eosinophilic matrix containing club-like projections. This histologic appearance is commonly referred to as the Splendore-Hoeppli phenomenon, although it may not always be present  (<a class="graphic graphic_picture graphicRef97217" href="/z/d/graphic/97217.html" rel="external">picture 2</a>) [<a href="#rid22">22,28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiographic studies may be useful to evaluate the size and extent of involvement. Pulmonary lesions may be present as a consolidation or mass lesion  (<a class="graphic graphic_picture graphicRef97225" href="/z/d/graphic/97225.html" rel="external">picture 3</a>), while other forms of visceral botryomycosis usually present as a mass lesion.</p><p></p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>In general, patients should receive antibiotic therapy until signs and symptoms of infection have resolved. A few weeks of therapy may be sufficient for those with superficial infection; patients with deep infections and/or those with underlying immunodeficiency may require months of therapy. Prolonged antibiotic therapy may be necessary in cases for which debridement is incomplete or not feasible. In such situations, antibiotic penetration to the organisms sequestered in the granules may be poor or limited [<a href="#rid20">20</a>].</p><p>Selection of antibiotics should be tailored to culture and susceptibility results. There is no conclusive evidence regarding the appropriate duration of therapy; most information on the duration of treatment of botryomycosis is anecdotal [<a href="#rid20">20</a>]. The duration of therapy described in case reports has ranged from weeks to months. In general, antibiotic therapy is continued until the clinical and radiographic (if applicable) signs of infection have resolved. </p><p class="headingAnchor" id="H10"><span class="h2">Cutaneous disease</span><span class="headingEndMark"> — </span>Treatment of cutaneous disease requires antibiotic therapy and, in most cases, surgical debridement. Antibiotic therapy alone may be sufficient for patients with superficial disease if a bacterial pathogen has been identified and malignancy has been excluded. For gram-positive infections, including <em>S. aureus</em>, oral <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (two double-strength tablets twice daily) can be used. Depending on culture and susceptibility data, other alternative agents include <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg twice daily), <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">minocycline</a> (100 mg twice daily), <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a> (500 mg four times daily), <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> (500 mg four times daily), <a class="drug drug_general" data-topicid="9349" href="/z/d/drug information/9349.html" rel="external">dicloxacillin</a> (500 mg every six hours), flucloxacillin (500 mg every six hours), or <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> (600 mg every 12 hours). Linezolid should be avoided for durations longer than two weeks due to increased risk of adverse events, such a cytopenia and peripheral neuropathy.</p><p>For pseudomonal infections, we recommend initiating therapy with <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> (2 g intravenously [IV] every 8 hours), <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> (2 g IV every 8 hours), <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> (2 g IV every 8 hours), or <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> (500 mg IV every 6 hours). If the isolate is fluoroquinolone sensitive, therapy may be switched to oral <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> (750 mg twice daily).</p><p>For infections due to other gram-negative organisms (<em>E. coli</em>, <em>Serratia</em>, <em>Proteus</em>), <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> (1 to 2 g once daily), <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> (2 g IV every 8 hours), <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> (500 mg IV every 6 hours), or <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a> 1 gm IV every 24 hours can be used initially until susceptibility data is available; oral <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> (500 mg twice daily) can be used if the isolate is susceptible.</p><p>In patients with superficial infection, antibiotic therapy is usually continued for one to two months or until all signs of infection have resolved. Surgical debridement together with antibiotic therapy is appropriate for lesions that extend into deep tissues such as muscle or bone, for lesions that do not improve with antibiotics alone, and for immunocompromised patients.</p><p class="headingAnchor" id="H11"><span class="h2">Visceral disease</span><span class="headingEndMark"> — </span>Treatment of visceral disease requires a combination of surgical and antimicrobial therapy. Resection of the mass often occurs prior to diagnosis given concern for malignancy in most cases of visceral disease.</p><p>For <em>S. aureus</em> and other gram-positive infections, we recommend initiating therapy with IV <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 1</a>). For <em>S. aureus</em> isolates sensitive to methicillin, a beta-lactam agent such as <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a> or flucloxacillin (2 g IV every four to six hours), or <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> (2 g IV every eight hours), should be used. Patients can be switched to oral antibiotics once the infection is debrided surgically and susceptibility data are available.</p><p>Antibiotic selection for pseudomonal and other gram-negative infections is similar to the recommendations for cutaneous infections. Therapy is usually continued for several months until all signs of infection have resolved.</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Botryomycosis is a chronic suppurative infection characterized by a granulomatous inflammatory response to bacterial pathogens that is observed most commonly among immunocompromised patients. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – The most common pathogen is <em>Staphylococcus aureus</em>; other pathogens have also been implicated. The pathogenesis of botryomycosis is not fully understood; it is thought to involve a combination of factors including an inciting event (such as trauma), the number of organisms inoculated, the virulence of the infecting pathogen, and host susceptibility to infection. (See <a class="local">'Microbiology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous disease</strong> – Cutaneous botryomycosis may present with subcutaneous nodules, verrucous lesions, or nonhealing ulcers associated with draining sinuses or fistulae. Drainage from the lesion is usually purulent and contains small yellowish grains resembling the sulfur granules seen in actinomycosis. (See <a class="local">'Cutaneous disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Visceral disease</strong> – Visceral botryomycosis occurs most commonly in the lung, although involvement of other organs including liver, spleen, kidney, and brain has also been described. (See <a class="local">'Visceral disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Botryomycosis may be difficult to distinguish from mycetoma, actinomycosis, malignancy, and other conditions. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of botryomycosis may be established by identifying nonfilamentous bacteria in granules in pus from draining sinuses, identifying nonfilamentous bacteria in granules in biopsy specimens, or culturing bacteria from ulcers or exudates in patients with clinical findings of botryomycosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of cutaneous disease requires antibiotic therapy and may also require surgical debridement, while treatment of visceral disease requires both surgical and antimicrobial therapy. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – There is no conclusive evidence regarding the appropriate duration of therapy. In general, patients should receive antibiotic therapy until signs and symptoms of infection have resolved. For superficial infection, a few weeks may be sufficient, while patients with deep infection and/or immunodeficiency may require a prolonged course of therapy. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">WINSLOW DJ. Botryomycosis. Am J Pathol 1959; 35:153.</a></li><li><a class="nounderline abstract_t">Bersoff-Matcha SJ, Roper CC, Liapis H, Little JR. Primary pulmonary botryomycosis: case report and review. Clin Infect Dis 1998; 26:620.</a></li><li><a class="nounderline abstract_t">Williams RH, Kattih M, Boyd WP, Morgan MB. Cecal botryomycosis: case report and review. Gastrointest Endosc 2003; 57:783.</a></li><li><a class="nounderline abstract_t">Sirka CS, Dash G, Pradhan S, et al. Cutaneous Botryomycosis in Immunocompetent Patients: A Case Series. Indian Dermatol Online J 2019; 10:311.</a></li><li><a class="nounderline abstract_t">Bender-Saebelkampf S, Franke I, Alter M, et al. Cutaneous and pulmonary botryomycosis. Lancet Infect Dis 2019; 19:670.</a></li><li><a class="nounderline abstract_t">Brunken RC, Lichon-Chao N, van der Broek H. Immunologic abnormalities in botryomycosis. A case report with review of the literature. J Am Acad Dermatol 1983; 9:428.</a></li><li><a class="nounderline abstract_t">Patterson JW, Kitces EN, Neafie RC. Cutaneous botryomycosis in a patient with acquired immunodeficiency syndrome. J Am Acad Dermatol 1987; 16:238.</a></li><li><a class="nounderline abstract_t">Buescher ES, Hebert A, Rapini RP. Staphylococcal botryomycosis in a patient with the hyperimmunoglobulin E-recurrent infection syndrome. Pediatr Infect Dis J 1988; 7:431.</a></li><li><a class="nounderline abstract_t">Yörükoğlu K, Ozer E, Sade M, et al. Renal botryomycosis mimicking renal cell carcinoma. J Urol 1998; 159:2076.</a></li><li><a class="nounderline abstract_t">Katapadi K, Pujol F, Vuletin JC, et al. Pulmonary botryomycosis in a patient with AIDS. Chest 1996; 109:276.</a></li><li><a class="nounderline abstract_t">Paz HL, Little BJ, Ball WC Jr, Winkelstein JA. Primary pulmonary botryomycosis. A manifestation of chronic granulomatous disease. Chest 1992; 101:1160.</a></li><li><a class="nounderline abstract_t">Hacker P. Botryomycosis. Int J Dermatol 1983; 22:455.</a></li><li><a class="nounderline abstract_t">Olmstead PM, Finn M. Botryomycosis in pierced ears. Arch Dermatol 1982; 118:925.</a></li><li><a class="nounderline abstract_t">Hodgson R, Blackmore SA, Clarke CP. Pulmonary botryomycosis: a difficult diagnosis in the preoperative patient. J Thorac Cardiovasc Surg 2005; 130:924.</a></li><li><a class="nounderline abstract_t">Magrou J. Les formes actinomycotiques du staphylocoque. Annales de l'Institute Pasteur 1919; 33:344.</a></li><li><a class="nounderline abstract_t">Shults FS, Estes PC, Franklin JA, Richter CB. Staphylococcal botryomycosis in a specific-pathogen-free mouse colony. Lab Anim Sci 1973; 23:36.</a></li><li><a class="nounderline abstract_t">A diabetic man with a palpable abdominal wall mass. Clin Infect Dis 2006; 42:1157.</a></li><li><a class="nounderline abstract_t">Mehregan DA, Su WP, Anhalt JP. Cutaneous botryomycosis. J Am Acad Dermatol 1991; 24:393.</a></li><li><a class="nounderline abstract_t">Machado CR, Schubach AO, Conceição-Silva F, et al. Botryomycosis. Dermatology 2005; 211:303.</a></li><li><a class="nounderline abstract_t">Neafie RC, Marty AM. Unusual infections in humans. Clin Microbiol Rev 1993; 6:34.</a></li><li><a class="nounderline abstract_t">Small IA, Kobernick S. Botryomycosis of the tongue. Report of a case. Oral Surg Oral Med Oral Pathol 1967; 24:503.</a></li><li><a class="nounderline abstract_t">de Vries HJ, van Noesel CJ, Hoekzema R, Hulsebosch HJ. Botryomycosis in an HIV-positive subject. J Eur Acad Dermatol Venereol 2003; 17:87.</a></li><li><a class="nounderline abstract_t">Salvemini JN, Baldwin HE. Botryomycosis in a patient with acquired immunodeficiency syndrome. Cutis 1995; 56:158.</a></li><li><a class="nounderline abstract_t">Kathir K, Dennis C. Primary pulmonary botryomycosis: an important differential diagnosis for lung cancer. Respirology 2001; 6:347.</a></li><li><a class="nounderline abstract_t">Vasishta RK, Gupta N, Kakkar N. Botryomycosis--a series of six integumentary or visceral cases from India. Ann Trop Med Parasitol 2004; 98:623.</a></li><li><a class="nounderline abstract_t">Wu WQ, Cattaneo EA, Lapi A, Halde C. Botryomycosis: first report of human brain involvement. South Med J 1978; 71:1530.</a></li><li><a class="nounderline abstract_t">Gillock CB, Sahni KS, Mumaw VR, Meier FA. Cerebral botryomycosis: case study. J Infect Dis 1990; 162:765.</a></li><li><a class="nounderline abstract_t">Font RL, Hunts JH. Botryomycosis of limbal conjunctiva with Splendore-Hoeppli phenomenon. Arch Ophthalmol 1996; 114:1006.</a></li><li><a class="nounderline abstract_t">Schlossberg D, Pandey M, Reddy R. The Splendore-Hoeppli phenomenon in hepatic botryomycosis. J Clin Pathol 1998; 51:399.</a></li></ol></div><div id="topicVersionRevision">Topic 7649 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13617416" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Botryomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9524833" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Primary pulmonary botryomycosis: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12739561" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cecal botryomycosis: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31149580" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cutaneous Botryomycosis in Immunocompetent Patients: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122782" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cutaneous and pulmonary botryomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6355210" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Immunologic abnormalities in botryomycosis. A case report with review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819060" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cutaneous botryomycosis in a patient with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3393403" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Staphylococcal botryomycosis in a patient with the hyperimmunoglobulin E-recurrent infection syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9598524" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Renal botryomycosis mimicking renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8549198" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pulmonary botryomycosis in a patient with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1555442" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Primary pulmonary botryomycosis. A manifestation of chronic granulomatous disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6642829" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Botryomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7138052" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Botryomycosis in pierced ears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16153967" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pulmonary botryomycosis: a difficult diagnosis in the preoperative patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Les formes actinomycotiques du staphylocoque</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4347756" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Staphylococcal botryomycosis in a specific-pathogen-free mouse colony.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16594101" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A diabetic man with a palpable abdominal wall mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2061434" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cutaneous botryomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16205084" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Botryomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8457979" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Unusual infections in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5235476" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Botryomycosis of the tongue. Report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12602981" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Botryomycosis in an HIV-positive subject.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565600" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Botryomycosis in a patient with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844127" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Primary pulmonary botryomycosis: an important differential diagnosis for lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15324468" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Botryomycosis--a series of six integumentary or visceral cases from India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/725632" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Botryomycosis: first report of human brain involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2388002" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cerebral botryomycosis: case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694707" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Botryomycosis of limbal conjunctiva with Splendore-Hoeppli phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708210" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The Splendore-Hoeppli phenomenon in hepatic botryomycosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
